Tenosynovial Giant Cell Tumor disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: TNS001 MIFTS: 40	Tenosynovial Giant Cell Tumor Categories: Bone diseases, Cancer diseases, Muscle diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Tenosynovial Giant Cell Tumor

MalaCards integrated aliases for Tenosynovial Giant Cell Tumor:

Name: Tenosynovial Giant Cell Tumor ¹² ¹⁵ ¹⁷

Fibrous Histiocytoma of Tendon Sheath ¹² ⁷¹

Giant Cell Tumour of Tendon Sheath ¹²

Giant Cell Tumor of Tendon Sheath ¹²

Giant Cell Tumour of Tenosynovium ¹²

Giant Cell Tumor of Tenosynovium ¹²

Tenosynovial Giant Cell Tumour ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Bone diseases Muscle diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:314

ICD9CM ³⁴ 727.02

MeSH ⁴³ D000070779

NCIt ⁴⁹ C3402

SNOMED-CT ⁶⁷ 310605004

EFO ¹⁷ EFO_1000562

UMLS ⁷¹ C1318543

Sources

Summaries for Tenosynovial Giant Cell Tumor

MalaCards based summary : Tenosynovial Giant Cell Tumor, also known as fibrous histiocytoma of tendon sheath, is related to pigmented villonodular synovitis and malignant giant cell tumor of the tendon sheath. An important gene associated with Tenosynovial Giant Cell Tumor is CSF1 (Colony Stimulating Factor 1), and among its related pathways/superpathways are Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions and Hematopoietic cell lineage. The drugs Sargramostim and Grapefruit Seed Extract have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and brain, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : ⁷⁴ Pigmented villonodular synovitis (PVNS) , also known as intra-articular giant-cell tumor of the tendon... more...

Sources

Related Diseases for Tenosynovial Giant Cell Tumor

Diseases related to Tenosynovial Giant Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)

#	Related Disease	Score	Top Affiliating Genes
1	pigmented villonodular synovitis	33.5	SERPINA3 CSF1R CSF1 CD68
2	malignant giant cell tumor of the tendon sheath	32.7	CSF1R CSF1 COL6A3 CD68
3	villonodular synovitis	32.0	CSF1 CD68
4	benign giant cell tumor	31.2	USP6 SERPINA3 CSF1R CSF1 CD68
5	nodular tenosynovitis	30.9	SERPINA3 AKTIP
6	giant cell reparative granuloma	30.6	USP6 SERPINA3 CD68
7	multicentric reticulohistiocytosis	30.6	SERPINA3 CSF1 CD68
8	pleomorphic lipoma	30.5	SERPINA3 CD68 CD34
9	lipomatosis, multiple	30.3	SERPINA3 KIT CD34
10	bone giant cell tumor	30.2	USP6 SERPINA3 CSF1 CD68
11	desmoid tumor	30.1	KIT CDKN2A CD34
12	fibroma	30.1	USP6 SERPINA3 CD68 CD34
13	muscle cancer	30.0	SERPINA3 KIT CD34
14	sarcoma, synovial	29.9	SERPINA3 KIT CD34
15	malignant peripheral nerve sheath tumor	29.8	KIT CDKN2A CD34
16	fibrous histiocytoma	29.4	SERPINA3 KIT CD68 CD34 CD163
17	pseudosarcomatous fibromatosis	29.2	USP6 SERPINA3 CD68 CD34 AKTIP
18	plica syndrome	10.9
19	synovitis	10.9
20	bone giant cell sarcoma	10.4	CSF1 CD163
21	verruciform xanthoma of skin	10.4	SERPINA3 CD68
22	congenital epulis	10.4	SERPINA3 CD68
23	epulis	10.4	SERPINA3 CD68
24	tenosynovitis	10.4
25	lymphohistiocytoid mesothelioma	10.4	CDKN2A CD68
26	xanthogranulomatous pyelonephritis	10.4	SERPINA3 CD68
27	malignant inflammatory fibrous histiocytoma	10.4	SERPINA3 CD68
28	pancreas sarcoma	10.4	SERPINA3 CD68
29	primary cutaneous b-cell lymphoma	10.4	CDKN2B CDKN2A
30	xanthogranulomatous cholecystitis	10.4	SERPINA3 CD68
31	interdigitating dendritic cell sarcoma	10.4	SERPINA3 CD68
32	malignant giant cell tumor	10.4
33	hemosiderosis	10.4
34	chondroblastoma	10.4
35	spondylarthropathy	10.4	CSF1 CD163
36	cervical adenoid cystic carcinoma	10.3	KIT CDKN2A
37	langerhans cell sarcoma	10.3	CD68 CD163
38	melanoma-astrocytoma syndrome	10.3	CDKN2B CDKN2A
39	necrobiosis lipoidica	10.3	CD68 CD163
40	balloon cell malignant melanoma	10.3	CD68 CD163
41	hemangioma	10.3
42	laryngeal small cell carcinoma	10.3	KIT CDKN2A
43	chondrosarcoma	10.3
44	chromosomal triplication	10.3
45	rare soft tissue tumor	10.3
46	thyroid carcinoma	10.3
47	cutaneous solitary mastocytoma	10.3	SERPINA3 KIT
48	axillary lipoma	10.3	KIT CD68
49	type c thymoma	10.3	SERPINA3 KIT
50	small intestinal sarcoma	10.3	KIT CD68

Graphical network of the top 20 diseases related to Tenosynovial Giant Cell Tumor:

Sources

Symptoms & Phenotypes for Tenosynovial Giant Cell Tumor

MGI Mouse Phenotypes related to Tenosynovial Giant Cell Tumor:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.17	AKTIP CCR2 CD163 CD34 CDKN2A CDKN2B
2	homeostasis/metabolism	MP:0005376	10.15	AKTIP CCR2 CD163 CD34 CDKN2A CDKN2B
3	hematopoietic system	MP:0005397	10.1	CCR2 CD163 CD34 CD68 CDKN2A CDKN2B
4	immune system	MP:0005387	10.1	AKTIP CCR2 CD163 CD34 CD68 CDKN2A
5	integument	MP:0010771	9.86	AKTIP CD34 CDKN2A CDKN2B CSF1 CSF1R
6	neoplasm	MP:0002006	9.63	AKTIP CCR2 CD34 CDKN2A CDKN2B KIT
7	no phenotypic analysis	MP:0003012	9.56	CCR2 CD68 CDKN2A CDKN2B CSF1 CSF1R
8	skeleton	MP:0005390	9.23	AKTIP CCR2 CD68 CDKN2A COL6A3 CSF1

Sources

Drugs & Therapeutics for Tenosynovial Giant Cell Tumor

Drugs for Tenosynovial Giant Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sargramostim

Approved, Investigational

Phase 3

83869-56-1, 123774-72-1

Synonyms:

123774-72-1

D05803

Leukine

Leukine (TN)

Recombinant human granulocyte-macrophage colony stimulating factor

rGM-CSF

rHu GM-CSF

Sargramostim

Sargramostim (genetical recombination)

Sargramostim (genetical recombination) (JAN)

Sargramostim (USAN/INN)

Grapefruit Seed Extract

Phase 2

Immunoglobulins

Phase 1, Phase 2

Antibodies

Phase 1, Phase 2

Paclitaxel

Approved, Vet_approved

Phase 1

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Albumin-Bound Paclitaxel

Phase 1

Tubulin Modulators

Phase 1

Antimitotic Agents

Phase 1

Interventional clinical trials:

(show all 12)

#	Name	Status	NCT ID	Phase	Drugs
1	A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath	Active, not recruiting	NCT02371369	Phase 3	Pexidartinib;Placebo
2	A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)	Completed	NCT01643850	Phase 2	MCS110;Placebo
3	Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)	Completed	NCT01261429	Phase 2	Tasigna
4	A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor	Recruiting	NCT03069469	Phase 1, Phase 2	DCC-3014
5	A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES	Recruiting	NCT02554812	Phase 2	Avelumab;Utomilumab;PF-04518600;PD 0360324;CMP-001
6	A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)	Active, not recruiting	NCT02471716	Phase 1, Phase 2
7	A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor	Active, not recruiting	NCT01207492	Phase 2	nilotinib
8	Open-Label, Multicenter, Dose Escalation Phase Ia/Ib Study With Expansion Phase to Evaluate Safety, Pharmacokinetics and Activity of RO5509554, Administered as an Intravenous Infusion as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors	Completed	NCT01494688	Phase 1	Paclitaxel;RO5509554
9	A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)	Terminated	NCT02673736	Phase 1	PLX73086
10	A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors	Terminated	NCT01804530	Phase 1	PLX7486 TsOH
11	An Open-label, Single-dose Study to Assess the Pharmacokinetics of Pexidartinib in Subjects With Moderate Hepatic Impairment Compared to Healthy Subjects	Recruiting	NCT04223635	Early Phase 1	Pexidartinib
12	A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS)	Active, not recruiting	NCT02948088

Search NIH Clinical Center for Tenosynovial Giant Cell Tumor

Sources

Genetic Tests for Tenosynovial Giant Cell Tumor

Sources

Anatomical Context for Tenosynovial Giant Cell Tumor

MalaCards organs/tissues related to Tenosynovial Giant Cell Tumor:

⁴⁰

Bone, Breast, Brain, Thyroid, Salivary Gland

Sources

Publications for Tenosynovial Giant Cell Tumor

Articles related to Tenosynovial Giant Cell Tumor:

(show top 50) (show all 193)

#	Title	Authors	PMID	Year
1	Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon's Perspective. ⁶¹	Bernthal NM...Burke ZDC	32494892	2020
2	Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. ⁶¹	Baldi GG...Stacchiotti S	32478598	2020
3	Tenosynovial Giant Cell Tumor, Localized Type With Extensive Chondroid Metaplasia: A Case Report With Immunohistochemical and Molecular Genetic Analysis. ⁶¹	Nagase M...Maruyama R	31771368	2020
4	Tenosynovial Giant Cell Tumor in the Hand: Experience with 173 Cases. ⁶¹	Cevik HB...Gumustas SA	32312203	2020
5	PK/PD mediated dose optimization of emactuzumab, a CSF1R inhibitor, in patients with advanced solid tumors and diffuse-type tenosynovial giant cell tumor. ⁶¹	Smart K...Meneses-Lorente G	32575160	2020
6	Tenosynovial Giant Cell Tumor in an Infant. ⁶¹	Shahriari S...Shetty A	32472881	2020
7	Shoulder Tumor/Tumor-Like Lesions: What to Look for. ⁶¹	Hallinan JTPD...Huang BK	32241665	2020
8	Tenosynovial giant cell tumor mimicking an ankle monoarthritis. ⁶¹	Vilchez-Oya F...Pros A	32384050	2020
9	Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy. ⁶¹	Palmerini E...Staals EL	32297819	2020
10	Tenosynovial Giant Cell Tumor of Temporomandibular Joint and Skull Base Presenting as Ear Canal Mass. ⁶¹	Vassalli G...Lim JH	30955370	2020
11	Unusual manifestations of diffuse-type tenosynovial giant cell tumor in two patients: importance of radiologic-pathologic correlation. ⁶¹	Dundar A...Broski SM	31656976	2020
12	Soft Tissue Special Issue: Giant Cell-Rich Lesions of the Head and Neck Region. ⁶¹	Lee JC...Huang HY	31950466	2020
13	Uncommon tumors of temporomandibular joint: An institutional experience and review. ⁶¹	Hamza A...Bell D	32040228	2020
14	Intraarticular Nodular Fasciitis of the Knee With MHY9-USP6 Fusion: A Case Report. ⁶¹	Igrec J...Liegl-Atzwanger B	32089028	2020
15	A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. ⁶¹	Lee JH...Lin CC	30825104	2020
16	Monoarticular, Multifocal, Localized Tenosynovial Giant Cell Tumor of the Knee: A Case Report. ⁶¹	Tedesco AJ...Tedesco NS	32044773	2020
17	Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development. ⁶¹	Benner B...Wesolowski R	32440095	2020
18	Incomplete resection increases the risk of local recurrence and negatively affects functional outcome in patients with tenosynovial giant cell tumor of the hindfoot. ⁶¹	Tsukamoto S...Tanaka Y	31839476	2019
19	KRAS mutant tenosynovial giant cell tumor in a pediatric patient: a case report. ⁶¹	Mankuzhy NP...Mody R	31993359	2019
20	Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations. ⁶¹	Tsuda Y...Matsuda K	31107544	2019
21	Molecular Profiling of Atypical Tenosynovial Giant Cell Tumors Reveals Novel Non-CSF1 Fusions. ⁶¹	Vougiouklakis T...Jour G	31906059	2019
22	Risk Factors Associated With Postoperative Recurrence in Patients With Tenosynovial Giant Cell Tumor of the Hand: A Retrospective Cohort Study. ⁶¹	Shi J...Yan H	31524641	2019
23	Pexidartinib: First Approval. ⁶¹	Lamb YN	31602563	2019
24	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. ⁶¹	Verspoor FGM...Cassier PA	31601938	2019
25	Tenosynovial giant cell tumor in the foot and ankle. ⁶¹	Cevik HB...Gumustas SA	31526689	2019
26	The surgical outcome and recurrence rate of tenosynovial giant cell tumor in the elbow: a literature review. ⁶¹	Al Farii H...Turcotte R	31447124	2019
27	A Pregnant Woman With Multi-fragmented Giant Cell Tumor of Tendon Sheath: A Rare Anatomical Location. ⁶¹	Arican M...Turhan Y	31486673	2019
28	Diffuse-Type Tenosynovial Giant Cell Tumor of the Thoracic Spine: Appearance on FDG PET/CT. ⁶¹	Shen G...Kuang A	31274627	2019
29	Histologically benign metastasizing tenosynovial giant cell tumor mimicking metastatic malignancy: A case report and review of literature. ⁶¹	Chen EL...Xie KL	31193787	2019
30	Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints: A Study Based on a Multicenter-Pooled Database of 31 International Sarcoma Centers. ⁶¹	Mastboom MJL...Tenosynovial Giant Cell Tumors (TGCT) Study Group	31318811	2019
31	Intra-articular fibroma-like perivascular epithelioid tumor (PEComa) mimicking tenosynovial giant cell tumor, diffuse type. ⁶¹	Harvey JP...Bredella MA	30206676	2019
32	Diffuse Tenosynovial Giant Cell Tumor Around the Temporomandibular Joint: An Entity With Special Radiologic and Pathologic Features. ⁶¹	Wang JG...Liu J	30796908	2019
33	The effects of radiosynoviorthesis in pigmented villonodular synovitis of the knee. ⁶¹	Durr HR...Tiling R	30539286	2019
34	Diffuse-Type Tenosynovial Giant Cell Tumor of the Shoulder Evaluated by FDG PET/CT. ⁶¹	Tang K...Wang L	30624274	2019
35	Desmoplastic fibroblastoma mimicking tenosynovial giant cell tumor encasing a tendon of the foot. ⁶¹	Lee SM...Choi YR	30229348	2019
36	Diffuse-Type Tenosynovial Giant Cell Tumor of the Thoracic Spine: Appearance on FDG PET/CT. ⁶¹	Shen G...Kuang A	30889006	2019
37	Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol. ⁶¹	Takeuchi A...Tsuchiya H	30738433	2019
38	Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes. ⁶¹	Al-Ibraheemi A...Folpe AL	30206409	2019
39	Tenosynovial giant cell tumor of the cervical spine: a case report. ⁶¹	Furuhata R...Watanabe K	32094332	2019
40	The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS). ⁶¹	Gelhorn HL...Tap WD	30714073	2019
41	Giant Cell Poor Extra-Articular Diffuse-Type Tenosynovial Giant Cell Tumor With Extensive Desmin Expression: A Potential Diagnostic Pitfall With Cytogenetic Confirmation. ⁶¹	Lopez L...John I	30019981	2019
42	Imaging features of phosphaturic mesenchymal tumors. ⁶¹	Broski SM...Wenger DE	29987349	2019
43	Clinical and morphological correlations and histopathology of joint damage in patients with diffuse-type tenosynovial giant cell tumor. ⁶¹	Dyadyk OO...Hryhorovska AV	32124739	2019
44	Tenosynovial giant cell tumor of the cervical spine: a case report. ⁶¹	Furuhata R...Watanabe K	31240119	2019
45	Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors. ⁶¹	Zheng B...Yan W	31933896	2019
46	Significance of incidental intra-articular and peri-articular FDG avid foci on PET/CT. ⁶¹	Cohen-Levy WB...Jose J	29665710	2019
47	A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. ⁶¹	Piawah S...Chien AJ	31240240	2019
48	Concomitant Spondyloarthritis and Tenosynovial Giant Cell Tumor in Pigmented Villonodular Synovitis Challenging Cases. ⁶¹	Manetti M...Bandinelli F	30601200	2018
49	Extra-articular tenosynovial giant cell tumor of diffuse type in the temporal area with brain parenchymal invasion: a case report. ⁶¹	Son SM...Woo CG	29334779	2018
50	Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy. ⁶¹	Nakayama R...Wagner AJ	30594158	2018

Sources

Genes for Tenosynovial Giant Cell Tumor

Genes related to Tenosynovial Giant Cell Tumor (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CSF1	Colony Stimulating Factor 1	Protein Coding	15.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	10.48	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	SERPINA3	Serpin Family A Member 3	Protein Coding	10.33	DISEASES inferred ¹⁵ ¹⁵
4	CSF1R	Colony Stimulating Factor 1 Receptor	Protein Coding	7.84	DISEASES inferred ¹⁵
5	COL6A3	Collagen Type VI Alpha 3 Chain	Protein Coding	7.56	DISEASES inferred ¹⁵
6	CD68	CD68 Molecule	Protein Coding	6.72	DISEASES inferred ¹⁵
7	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	6.6	GeneCards inferred via : Publications (show sections)
8	CD163	CD163 Molecule	Protein Coding	6.31	DISEASES inferred ¹⁵
9	IL34	Interleukin 34	Protein Coding	6.18	DISEASES inferred ¹⁵
10	USP6	Ubiquitin Specific Peptidase 6	Protein Coding	5.48	DISEASES inferred ¹⁵
11	CLU	Clusterin	Protein Coding	5.47	DISEASES inferred ¹⁵
12	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	5.38	DISEASES inferred ¹⁵
13	CD34	CD34 Molecule	Protein Coding	5.28	DISEASES inferred ¹⁵
14	AKTIP	AKT Interacting Protein	Protein Coding	5.25	DISEASES inferred ¹⁵
15	CCR2	C-C Motif Chemokine Receptor 2	Protein Coding	5.24	DISEASES inferred ¹⁵
16	SLC43A3	Solute Carrier Family 43 Member 3	Protein Coding	5.18	DISEASES inferred ¹⁵

Sources

Variations for Tenosynovial Giant Cell Tumor

Sources

Expression for Tenosynovial Giant Cell Tumor

Search GEO for disease gene expression data for Tenosynovial Giant Cell Tumor.

Sources

Pathways for Tenosynovial Giant Cell Tumor

Pathways related to Tenosynovial Giant Cell Tumor according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁴ Show member pathways Chemokine receptors bind chemokines ⁶⁵ Viral protein interaction with cytokine and cytokine receptor ³⁶	11.96	IL34 CSF1R CSF1 CCR2
2	Hematopoietic cell lineage ³⁶	11.45	KIT CSF1R CSF1 CD34
3	C-MYB transcription factor network ¹	11.44	KIT CSF1R CD34
4	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁴	11.42	KIT CSF1 CD68 CD34 CD163
5	Differentiation Pathway ¹	11.11	KIT CSF1R CSF1
6	Dendritic Cells Developmental Lineage Pathway ⁶⁴	10.89	KIT CSF1R CSF1 CD34 CD163
7	LDL Oxidation in Atherogenesis ⁶³	10.61	CSF1 CD68

Sources

GO Terms for Tenosynovial Giant Cell Tumor

Cellular components related to Tenosynovial Giant Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	CSF1-CSF1R complex	GO:1990682	8.62	CSF1R CSF1

Biological processes related to Tenosynovial Giant Cell Tumor according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.8	KIT IL34 CSF1 CLU CDKN2A CD34
2	cytokine-mediated signaling pathway	GO:0019221	9.77	KIT IL34 CSF1R CSF1 CCR2
3	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	9.7	KIT CSF1R CSF1
4	negative regulation of phosphorylation	GO:0042326	9.51	CDKN2B CDKN2A
5	inflammatory response	GO:0006954	9.5	SERPINA3 KIT IL34 CSF1R CSF1 CD163
6	positive regulation of macrophage differentiation	GO:0045651	9.49	IL34 CSF1
7	positive regulation of monocyte differentiation	GO:0045657	9.48	IL34 CSF1
8	somatic stem cell division	GO:0048103	9.46	KIT CDKN2A
9	hemopoiesis	GO:0030097	9.46	KIT CSF1R CD34 CCR2
10	positive regulation of macrophage proliferation	GO:0120041	9.43	IL34 CSF1R
11	positive regulation of macrophage chemotaxis	GO:0010759	9.43	IL34 CSF1R CSF1
12	macrophage colony-stimulating factor signaling pathway	GO:0038145	9.4	CSF1R CSF1
13	microglial cell proliferation	GO:0061518	8.92	IL34 CSF1R CSF1 CLU

Molecular functions related to Tenosynovial Giant Cell Tumor according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	9.16	CDKN2B CDKN2A
2	cytokine binding	GO:0019955	9.13	KIT CSF1R CCR2
3	macrophage colony-stimulating factor receptor binding	GO:0005157	8.62	IL34 CSF1

Sources

Sources for Tenosynovial Giant Cell Tumor

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia